Corrigendum: The efficacy of furmonertinib in untreated advanced NSCLC patients with sensitive EGFR mutations in a real-world setting: a single institutional experience
Ningning Yan, Sanxing Guo, Siyuan Huang, Huixian Zhang, Xingya Li
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsLung Cancer Treatments and Mutations · Lymphoma Diagnosis and Treatment · Colorectal Cancer Treatments and Studies
In the published article, there was an error in the legend for Figure 2 as published. Furthermore, we have made the wrong graphical representation for Figure 2. The corrected figure and its legend appear below.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.